MedTrace Logo

Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC

NCT01639248 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2017-06-26

No results posted yet for this study

Summary

The purpose of this study is to determine the activity of ENMD-2076 as defined by the clinical benefit rate when patients with previously treated locally advanced or metastatic triple negative breast cancer are treated with daily oral ENMD-2076.

Conditions

Interventions

DRUG

ENMD-2076

250 mg per day in oral capsules in 28 day continuous cycles

Sponsors & Collaborators

  • University of Colorado, Denver

    collaborator OTHER

  • Indiana University Melvin and Bren Simon Cancer Center

    collaborator OTHER

  • CASI Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Rong Chen, MD · CASI Pharmaceuticals, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2017-06-30
Completion
2017-06-30

Countries

  • United States
  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01639248 on ClinicalTrials.gov